NIS4® Technology
Diagnosis of at-risk NASH (F≥2)
CommercialLaunched as LDT
Key Facts
About Genfit
GENFIT is a French biopharmaceutical company with a 20+ year history, pioneering research in nuclear receptors and metabolic diseases. Its strategic focus is on advancing elafibranor, a first-in-class PPAR agonist, through late-stage development for PBC and exploring its potential in other liver and metabolic conditions. The company is also commercializing NIS4®, a non-invasive blood-based diagnostic technology for NASH, and maintains a discovery pipeline fueled by its integrated research platform. GENFIT is publicly traded on the Euronext Paris and Nasdaq exchanges.
View full company profile